Idioma:

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

Alcoceba, Miguel ; Sebastián, Elena ; Marín, Luis ; Balanzategui, Ana ; Sarasquete, M. Eugenia ; Chillón, M. Carmen ; Jiménez, Cristina ; Puig, Noemí ; Corral, Rocío ; Pardal, Emilia ; Grande, Carlos ; Bello, José Luis ; Albo, Carmen ; de la Cruz, Fátima ; Panizo, Carlos ; Martín, Alejandro ; González-Barca, Eva ; Caballero, M. Dolores ; San Miguel, Jesús F. ; García-Sanz, Ramón ; González, Marcos

Blood, 2013-08, Vol.122 (8), p.1448-1454 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma
Autor: Alcoceba, Miguel ; Sebastián, Elena ; Marín, Luis ; Balanzategui, Ana ; Sarasquete, M. Eugenia ; Chillón, M. Carmen ; Jiménez, Cristina ; Puig, Noemí ; Corral, Rocío ; Pardal, Emilia ; Grande, Carlos ; Bello, José Luis ; Albo, Carmen ; de la Cruz, Fátima ; Panizo, Carlos ; Martín, Alejandro ; González-Barca, Eva ; Caballero, M. Dolores ; San Miguel, Jesús F. ; García-Sanz, Ramón ; González, Marcos
Assuntos: Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Case-Control Studies ; Cyclophosphamide - therapeutic use ; Disease-Free Survival ; Doxorubicin - therapeutic use ; Female ; Gene Frequency ; HLA Antigens - genetics ; HLA-DRB1 Chains - genetics ; Humans ; Lymphoma, Large B-Cell, Diffuse - diagnosis ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - genetics ; Male ; Middle Aged ; Phenotype ; Polymorphism, Genetic ; Prednisolone - therapeutic use ; Prognosis ; Risk Factors ; Rituximab ; Vincristine - therapeutic use ; Young Adult
É parte de: Blood, 2013-08, Vol.122 (8), p.1448-1454
Descrição: Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease influenced by genetic and environmental factors. The role of the HLA system in tumor antigen presentation could be involved in susceptibility and disease control. We analyzed the phenotypic frequencies of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 in 250 DLBCLs, comparing them with 1940 healthy individuals. We also evaluated the influence of HLA polymorphisms on survival in those patients treated with curative intention using cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)-like regimen without (n = 64, 26%) or with (n = 153, 61%) rituximab. DLBCL patients have a higher phenotypic frequency of HLA-DRB1*01 (29% vs 19.5%, P = .0008, Pc = .0104) and a lower frequency of HLA-C*03 (6.4% vs 17.9%, P < .0005, Pc = .007) compared with healthy individuals. Irrespective of the age-adjusted International Prognostic Index, those patients receiving a CHOP-like plus rituximab regimen and carrying the HLA-B44 supertype had worse 5-year progression-free (54% vs 71%, P = .019) and 5-year overall (71% vs 92%, P = .001) survival compared with patients without this supertype. Our data suggest that some HLA polymorphisms influence the development and outcome of DLBCL, allowing the identification of an extremely good-risk prognostic subgroup. However, these results are preliminary and need to be validated in order to exclude a possible population effect. •DLBCL patients carrying the HLA-B44 supertype have a worse progression-free and overall survival after R-CHOP-like treatment.•The HLA-DRB1*01 allele increases the risk of DLBCL development.
Editor: United States: Elsevier Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

United States: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.